Title: The anti-ulcer agent, irsogladine, increases insulin secretion by MIN6 cells.
Journal: European journal of pharmacology 20120615
Title: Irsogladine maleate ameliorates inflammation and fibrosis in mice with chronic colitis induced by dextran sulfate sodium.
Journal: Medical molecular morphology 20120601
Title: Irsogladine maleate regulates epithelial barrier function in tumor necrosis factor-α-stimulated human gingival epithelial cells.
Journal: Journal of periodontal research 20120201
Title: Comparison of the efficacy of irsogladine maleate and famotidine for the healing of gastric ulcers after Helicobacter pylori eradication therapy: a randomized, controlled, prospective study.
Journal: Scandinavian journal of gastroenterology 20110301
Title: Irsogladine maleate regulates neutrophil migration and E-cadherin expression in gingival epithelium stimulated by Aggregatibacter actinomycetemcomitans.
Journal: Biochemical pharmacology 20100515
Title: Clinical trial: irsogladine maleate, a mucosal protective drug, accelerates gastric ulcer healing after treatment for eradication of Helicobacter pylori infection--the results of a multicentre, double-blind, randomized clinical trial (IMPACT study).
Journal: Alimentary pharmacology & therapeutics 20100401
Title: Irsogladine Maleate in the management of recurrent aphthous stomatitis: a pilot study.
Journal: Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry 20100101
Title: Effect of irsogladine maleate on NSAID-induced reduction of gastric mucosal blood flow in anesthetized dogs.
Journal: Digestion 20090101
Title: Prophylactic effect of irsogladine maleate against indomethacin-induced small intestinal lesions in rats.
Journal: Digestive diseases and sciences 20081001
Title: Irsogladine maleate abolishes the increase in interleukin-8 levels caused by outer membrane protein 29 from Aggregatibacter (Actinobacillus) actinomycetemcomitans through the ERK pathway in human gingival epithelial cells.
Journal: Journal of periodontal research 20081001
Title: Irsogladine maleate suppresses indomethacin-induced elevation of proinflammatory cytokines and gastric injury in rats.
Journal: World journal of gastroenterology 20080814
Title: Irsogladine maleate counters the interleukin-1 beta-induced suppression in gap-junctional intercellular communication but does not affect the interleukin-1 beta-induced zonula occludens protein-1 levels in human gingival epithelial cells.
Journal: Journal of periodontal research 20080201
Title: Irsogladine maleate potentiates the effects of nitric oxide on activation of cAMP signalling pathways and suppression of mesangial cell mitogenesis.
Journal: British journal of pharmacology 20070601
Title: Anti-inflammatory agents in the management of alimentary mucositis.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20060601
Title: Regulation of IL-8 by Irsogladine maleate is involved in abolishment of Actinobacillus actinomycetemcomitans-induced reduction of gap-junctional intercellular communication.
Journal: Cytokine 20060601
Title: Microsphere-based protease assays and screening application for lethal factor and factor Xa.
Journal: Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501
Title: Effects of irsogladine on P450-isoform specific activities in human hepatic microsomes.
Journal: Arzneimittel-Forschung 20060101
Title: Irsogladine maleate influences the response of gap junctional intercellular communication and IL-8 of human gingival epithelial cells following periodontopathogenic bacterial challenge.
Journal: Biochemical and biophysical research communications 20050729
Title: Irsogladine, an anti-ulcer drug, suppresses superoxide production by inhibiting phosphodiesterase type 4 in human neutrophils.
Journal: Life sciences 20041119
Title: Phosphodiesterase inhibition by a gastroprotective agent irsogladine: preferential blockade of cAMP hydrolysis.
Journal: Life sciences 20040827
Title: Phosphodiesterase type IV inhibitors prevent ischemia-reperfusion-induced gastric injury in rats.
Journal: Journal of pharmacological sciences 20040701
Title: Irsogladine prevents monochloramine-induced gastric mucosal lesions by improving the decrease in mucosal blood flow due to the disturbance of nitric oxide synthesis in rats.
Journal: Journal of pharmacological sciences 20031101
Title: Therapeutic benefits of irsogladine maleate on aphthous stomatitis induced by methotrexate in rheumatoid arthritis.
Journal: The Journal of rheumatology 20030901
Title: [A case of idiopathic relapsing aphthous stomatitis which was effectively treated by irsogladine maleate].
Journal: Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20011201
Title: Suppressive effect of irsogladine maleate on N-methyl-N-nitro-N-nitrosoguanidine (MNNG)-initiated and glyoxal-promoted gastric carcinogenesis in rats.
Journal: Toxicology 20010914
Title: Ren, C.J., et al., Irsogladine maleate inhibits angiogenesis in wild-type and plasminogen activator-deficient mice. J Surg Res, 1998. 77(2): p. 126-31.
Title: Kawasaki, Y., et al., Irsogladine malate up-regulates gap junctional intercellular communication between pancreatic cancer cells via PKA pathway. Pancreas, 2002. 25(4): p. 373-7.
Title: Kyoi, T., et al., Phosphodiesterase inhibition by a gastroprotective agent irsogladine: preferential blockade of cAMP hydrolysis. Life Sci, 2004. 75(15): p. 1833-42.
